Jeffry Adiwidjaja

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 11

Top Venues

Pharmaceutical research

British journal of clinical pharmacology

Clinical pharmacology and therapeutics

European journal of clinical pharmacology

University of Sydney (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

University of Sydney Aug 08 2016

Australia

PHD :: Sydney Pharmacy School

Publications

Jeffry Adiwidjaja, Jessica Spires, Kim L R Brouwer
Physiologically Based Pharmacokinetic (PBPK) Model Predictions of Disease Mediated Changes in Drug Disposition in Patients with Nonalcoholic Fatty Liver Disease (NAFLD). Pharmaceutical research (2024)
Jeffry Adiwidjaja, Jessica Spires, Kim L R Brouwer
Physiologically Based Pharmacokinetic (PBPK) Model Predictions of Disease Mediated Changes in Drug Disposition in Patients with Nonalcoholic Fatty Liver Disease (NAFLD). Pharmaceutical research 41 (3) (2024)
Jeffry Adiwidjaja, Jessica Spires, Kim L R Brouwer
Physiologically Based Pharmacokinetic (PBPK) Model Predictions of Disease Mediated Changes in Drug Disposition in Patients with Nonalcoholic Fatty Liver Disease (NAFLD). Pharmaceutical research 41 (3) (2024)
Josephine A Adattini, Jeffry Adiwidjaja, Annette S Gross, Andrew J McLachlan
Application of physiologically based pharmacokinetic modeling to understand real-world outcomes in patients receiving imatinib for chronic myeloid leukemia. Pharmacology research & perspectives 11 (4) (2023)
Jeffry Adiwidjaja, Alan V Boddy, Andrew J McLachlan
Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib. European journal of clinical pharmacology 78 (4) (2022)
Jeffry Adiwidjaja, Josephine A Adattini, Alan V Boddy, Andrew J McLachlan
Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS-CoV-2 Infection: A Case Study With Imatinib. Journal of clinical pharmacology 62 (10) (2022)
William A Murphy, Jeffry Adiwidjaja, Noora Sjöstedt, Kyunghee Yang, James J Beaudoin, Jessica Spires, Scott Q Siler, Sibylle Neuhoff, Kim L R Brouwer
Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH). Clinical pharmacology and therapeutics (2022)
Jeffry Adiwidjaja, Lucy Sasongko
Effect of Nigella sativa oil on pharmacokinetics and pharmacodynamics of gliclazide in rats. Biopharmaceutics & drug disposition 42 (8) (2021)
Jeffry Adiwidjaja, Annette S Gross, Alan V Boddy, Andrew J McLachlan
Physiologically-based pharmacokinetic model predictions of inter-ethnic differences in imatinib pharmacokinetics and dosing regimens. British journal of clinical pharmacology (2021)
Jeffry Adiwidjaja, Alan V Boddy, Andrew J McLachlan
Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. British journal of clinical pharmacology 86 (10) (2020)
Xiaoqian Liu, David J Hunter, Jillian Eyles, Andrew J McLachlan, Jeffry Adiwidjaja, Shane K Eagles, XiaoSuo Wang
Pharmacokinetic assessment of constituents of Boswellia serrata, pine bark extracts, curcumin in combination including methylsulfonylmethane in healthy volunteers. The Journal of pharmacy and pharmacology 72 (1) (2019)

Jeffry Adiwidjaja.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jeffry Adiwidjaja